Sudeep Pharma (SUDEEPPHRM) Q4 24/25 earnings summary

Executive summary

• Consolidated revenue from operations reached ₹50,199.92 lakhs for FY 2024-25, up from ₹45,928.06 lakhs year-over-year.

• Net profit attributable to owners was ₹13,872.92 lakhs, compared to ₹13,321.00 lakhs in the previous year.

• The group continued to expand, including the acquisition of Sudeep Pharma B.V. and Sudeep Advanced Materials Pvt Ltd as wholly owned subsidiaries.

Financial highlights

• Total consolidated income: ₹51,132.83 lakhs (FY25) vs ₹46,537.74 lakhs (FY24).

• EBITDA: ₹19,343.55 lakhs (calculated as profit before tax plus depreciation and finance costs).

• Net profit margin: 27.6% (FY25) vs 29.0% (FY24).

• Earnings per share (diluted): ₹12.79 (FY25) vs ₹12.28 (FY24).

• Cash and cash equivalents at year-end: ₹3,680.71 lakhs.

Outlook and guidance

• The group filed a Draft Red Herring Prospectus for an IPO, aiming to raise ₹95 crore via fresh issue and an offer for sale.

• Proceeds will be used for capex at the Nandesari facility and general corporate purposes.

• Directors are optimistic about receiving regulatory approvals and continued growth in core markets.